Albert N. Marchio II Sells 1,000 Shares of Edge Therapeutics, Inc. (EDGE) Stock
Edge Therapeutics, Inc. (NASDAQ:EDGE) insider Albert N. Marchio II sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $10.39, for a total value of $10,390.00. Following the completion of the transaction, the insider now directly owns 5,861 shares in the company, valued at $60,895.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Edge Therapeutics, Inc. (NASDAQ EDGE) traded down 0.95% during midday trading on Friday, hitting $10.46. The stock had a trading volume of 231,756 shares. The firm’s 50-day moving average price is $10.56 and its 200 day moving average price is $9.86. The company’s market cap is $322.70 million. Edge Therapeutics, Inc. has a 12 month low of $7.30 and a 12 month high of $13.50.
Edge Therapeutics (NASDAQ:EDGE) last posted its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.44). On average, analysts expect that Edge Therapeutics, Inc. will post ($1.87) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/26/albert-n-marchio-ii-sells-1000-shares-of-edge-therapeutics-inc-edge-stock.html.
EDGE has been the topic of several recent analyst reports. BidaskClub raised Edge Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research lowered Edge Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd.
A number of hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System raised its stake in Edge Therapeutics by 7.7% in the second quarter. California State Teachers Retirement System now owns 35,167 shares of the biotechnology company’s stock worth $361,000 after buying an additional 2,500 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Edge Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock worth $186,000 after buying an additional 3,764 shares in the last quarter. State Street Corp raised its stake in Edge Therapeutics by 16.3% in the second quarter. State Street Corp now owns 277,352 shares of the biotechnology company’s stock worth $2,847,000 after buying an additional 38,909 shares in the last quarter. DAFNA Capital Management LLC bought a new stake in Edge Therapeutics during the second quarter worth $199,000. Finally, Janus Henderson Group PLC bought a new stake in Edge Therapeutics during the second quarter worth $21,962,000. Institutional investors own 48.68% of the company’s stock.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Stock Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related stocks with our FREE daily email newsletter.